What is the current North America Glucagon-like Peptide-1 Agonists Market size?

In 2024, the North America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 6.94 billion. Read More

Who are the key players in North America Glucagon-like Peptide-1 Agonists Market?

Astrazeneca, Sanofi, Eli Lilly and Company, Pfizer Inc. and Novo Nordisk A/S are the major companies operating in the North America Glucagon-like Peptide-1 Agonists Market. Read More

What years does this North America Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the North America Glucagon-like Peptide-1 Agonists Market size was estimated at USD 6.99 billion. The report covers the North America Glucagon-like Peptide-1 Agonists Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

North America GLP-1 Agonists Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers North America GLP-1 Drug Companies and the Market is Segmented Into Drugs (Dulaglutide (Trulicity), Exenatide (Byetta and Bydureon), Liraglutide (Victoza), Lixisenatide (Lyxumia), And Semaglutide (Ozempic)) and Geography (United States, Canada, And Rest of North America). The Market Provides the Value (in USD) and Volume (in Units) for the Above Segments.